Prevalence and Correlates of Symptoms of Cannabinoid Hyperemesis Syndrome in the United States, 2025.

Ilgen M.; Price A.; Goldman P.; Whittington B.; Hicks B. · American journal of public health · 2026

**Background & Methods** This was a cross-sectional review analyzing nationally representative survey data from 7,034 US adults collected between May-September 2025. The study employed survey-weighted multinomial logistic regression models to examine the prevalence of cannabinoid hyperemesis syndrome (CHS)-like symptoms and their associations with demographic characteristics, cannabis-use patterns, and cannabis-related problems. **Key Findings** • Overall CHS-like symptom prevalence was 2.7% among all respondents, but substantially higher at 17.8% among daily cannabis users, indicating a strong dose-response relationship between frequency of use and symptom manifestation. • Demographic disparities were evident: younger age, female gender, non-White racial/ethnic identity, lower income, and lower educational attainment were all independently associated with increased likelihood of CHS symptoms, even when compared to other daily cannabis users. • Cannabis use–related problems emerged as a significant predictor of CHS symptoms, suggesting that individuals experiencing negative consequences from cannabis use were disproportionately affected by CHS, highlighting potential clustering of cannabis-related harms. **Dosage & Administration** Not reported. **Safety & Adverse Effects** The study focused on CHS symptoms as the primary outcome of interest but did not provide detailed characterization of specific adverse effects or symptom severity profiles beyond classification into CHS-symptom groups. **Evidence Quality** This study has notable limitations. As a cross-sectional survey-based design, it cannot establish causality or temporal relationships between cannabis use patterns and CHS symptom development. The reliance on self-reported symptoms without clinical validation or confirmed CHS diagnosis may introduce recall bias and symptom misclassification. The study was published ahead of print with limited peer review visibility at the time of summary. However, strengths include the large nationally representative sample, rigorous survey weighting methodology, and multivariable analysis controlling for confounding variables. The findings provide valuable epidemiologic data suggesting CHS is an emerging public health concern warranting clinical attention and patient education, particularly among vulnerable populations with limited economic resources.

More recent cannabis research